Lupin completes Gavis acquisition

MUMBAI and BALTIMORE — Lupin announced Wednesday that it had completed its acquisition of Gavis, which includes Gavis Pharmaceuticals and Novel Laboratories, for about $880 million. 

 

Lupin said the acquisition will grow the company’s footprint in the U.S. generics market and expands its dermatology, controlled substance product and high value and niche generics pipeline. With the acquisition, Lupin also gains its first manufacturing site in the United States — Gavis’ New Jersey manufacturing facility. 

 

The new combined company will have over 120 products on the market and a pipeline with the fifth-largest number of abbreviated new drug application (ANDA) filings with the Food and Drug Administration. 

 

“We are very pleased to have completed our acquisition of Gavis,” Lupin CEO Vinita Gupta said. “The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin's generic as well as specialty pipeline.”